Prevalence of DNA Repair Gene Mutations in Blood and Tumor Tissue and Impact on Prognosis and Treatment in HNSCC

Prevalence of DNA Repair Gene Mutations in Blood and Tumor Tissue and Impact on Prognosis and Treatment in HNSCC

PARP inhibitors are currently approved for a limited number of cancers and targetable mutations in DNA damage repair (DDR) genes. In this single-institution retrospective study, the profiles of 170 patients with head and neck squamous cell cancer (HNSCC) and available tumor tissue DNA (tDNA) and cir...

Full description

Bibliographic Details
Main Authors: Kimberly M. Burcher, Andrew T. Faucheux, Jeffrey W. Lantz, Harper L. Wilson, Arianne Abreu, Kiarash Salafian, Manisha J. Patel, Alexander H. Song, Robin M. Petro, Thomas Lycan, Cristina M. Furdui, Umit Topaloglu, Ralph B. D’Agostino, Wei Zhang, Mercedes Porosnicu
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
HNSCC
ctDNA
tDNA
DDR genes
PARP inhibitors
Online Access:https://www.mdpi.com/2072-6694/13/13/3118

Internet

https://www.mdpi.com/2072-6694/13/13/3118

Similar Items